Read our Recent Headlines

April 23 Biotech Update- Shooting Out of the Earnings Gate

This was a relatively slow news day (compared to yesterday and Monday) but there is still a lot to talk about with the large cap earnings. The sector did not.

April 22- Building Some Momentum

Everyone loves biotechs again. Has the bottom been put in? Perhaps but there was a lot of damage done to the sector, so I would remain selective on buys and.

Dissecting the ASCO 2014 abstract titles

Today, the American Society for Clinical Oncology(ASCO) posted a link to the ASCO 2014 meeting planner[LINK]. The planner also includes all of the abstract titles at the meeting. ASCO 2014.

Catalyst Watch – Vol. 2, Edition 12 (4/18/14)

Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date published (or are noted),.

April 21 Biotech Update- Some Good News to Start the Week

You would think the morning after a holiday would not be too busy but I have been running around all morning trying to organize a number of different projects. Luckily.

High Cash / Share Stocks in Biotech (Part I)

Due to the sector sell-off in biotech, I thought it may be interesting to provide subscribers a list of high net cash per share stocks (basically cash and equivalents less.

April 16 Biotech Update- An Early Continuation But Still a Fragile Sector

This is another slow day (in terms of news) and this time I promise to keep it short and actually keep it short as the sector is so volatile right.


Quick Facts














Chimera Research Group provides completely independent and actionable investment and trading ideas backed by comprehensive fundamental research and analysis for listed companies in the biotech and pharmaceutical sectors. Our coverage focuses on early stage companies with impending FDA decisions or clinical trial results but also includes mid-to-large cap bio-pharma companies where there exists specific catalysts. Our Trade Ideas are designed to maximize the risk reward profile. Our Research Reports outline the top up-and-coming catalysts that represent the best opportunities for traders and investors.

The biopharmaceutical sector offers significant opportunities to generate big returns yet can be risky and difficult to navigate. Subscribe to Chimera Research Group and proceed with confidence.

Get Started!